Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a CDK4/6 inhibitor as part of combination therapy.

On May 15, 2025 , the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market.

Scientists are aiming to determine the composition and topology of physiological Ashwell-Morell receptor ligands. Their findings will help uncover the receptor's still-hidden secrets.

Cash and cash equivalents as of March 31, 2025 were $102.3 million. Due in part to the strategic restructuring and ...

A pioneering research study details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to ...

Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, ...